---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: American hospital formulary service (AHFS), or other drug classification"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: American hospital formulary service (AHFS), or other drug classification. Topics: WHO International Nonproprietary Name classification; U.S. regulatory classification: biologic and gene therapy reviewed by CBER; EU classification: advanced therapy investigational medicinal product, gene therapy. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/american-hospital-formulary-service-ahfs-or-other-drug-classification"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: American hospital formulary service (AHFS), or other drug classification

<a id="heading-2.1.2.4"></a>

## 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

### WHO International Nonproprietary Name classification

> “gene therapy (Huntington's disease)”

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.4-2"></a>

### U.S. regulatory classification: biologic and gene therapy reviewed by CBER

> “We believe that all our product candidates will be regulated as biological products, or biologics, and in particular, as gene therapies, and will be subject to such requirements and regulations under U.S. and foreign laws.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

> “Our alignment reflects the strength of our data and collaborative discussions with the staff and senior management at FDA’s Center for Biologics Evaluation and Research (CBER).”

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated)

<a id="topic-2.1.2.4-3"></a>

### EU classification: advanced therapy investigational medicinal product, gene therapy

| Field | Quoted record |
| --- | --- |
| Advanced Therapy IMP (ATIMP) | “Yes” |
| Gene therapy medical product | “Yes” |
| Committee on Advanced therapies (CAT) has issued a classification for this product | “No” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.4-4"></a>

### AHFS and Anatomical Therapeutic Chemical classification

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
